These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 17325965)
1. Pattern of factor VIII inhibitors in patients with hemophilia A in the north east of Iran. Modaresi AR; Torghabeh HM; Pourfathollah AA; Shooshtari MM; Yazdi ZR Hematology; 2006 Jun; 11(3):215-7. PubMed ID: 17325965 [TBL] [Abstract][Full Text] [Related]
2. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors. Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488 [TBL] [Abstract][Full Text] [Related]
3. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII. Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701 [TBL] [Abstract][Full Text] [Related]
4. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207 [TBL] [Abstract][Full Text] [Related]
5. Factor VIII haplotypes in severe hemophilia A patients in India. Pinto P; Ghosh K; Shetty S Ann Hematol; 2013 Jul; 92(7):999-1000. PubMed ID: 23262994 [No Abstract] [Full Text] [Related]
6. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Schimpf K; Schwarz P; Kunschak M Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845 [No Abstract] [Full Text] [Related]
7. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Qian J; Borovok M; Bi L; Kazazian HH; Hoyer LW Thromb Haemost; 1999 Feb; 81(2):240-4. PubMed ID: 10063999 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A]. Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068 [TBL] [Abstract][Full Text] [Related]
9. Inhibitor development in haemophilia A patients with inversion of the intron 22 of the factor VIII gene. Tizzano EF; Altisent C; Domènech M; Cornet M; Tusell J; Baiget M Thromb Haemost; 1996 Jul; 76(1):125-6. PubMed ID: 8819266 [No Abstract] [Full Text] [Related]
10. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Baglin T; Beacham E Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186 [No Abstract] [Full Text] [Related]
11. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Fakharzadeh SS; Kazazian HH Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409 [TBL] [Abstract][Full Text] [Related]
12. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia center. Kershaw G; Jayakodi D; Dunkley S Semin Thromb Hemost; 2009 Nov; 35(8):760-8. PubMed ID: 20169512 [TBL] [Abstract][Full Text] [Related]
13. Alloantibodies to factor VIII in haemophilia. Zakarija A; Harris S; Rademaker AW; Brewer J; Krudysz-Amblo J; Butenas S; Mann KG; Green D Haemophilia; 2011 Jul; 17(4):636-40. PubMed ID: 21299745 [TBL] [Abstract][Full Text] [Related]
14. Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay. Mondorf W; Ehrenforth S; Vigh Z; Last J; Tippmann G; Kreuz W; Scharrer I Vox Sang; 1994; 66(1):8-13. PubMed ID: 8146988 [TBL] [Abstract][Full Text] [Related]
15. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan. Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A; Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824 [TBL] [Abstract][Full Text] [Related]
16. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors. van den Berg HM Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280 [TBL] [Abstract][Full Text] [Related]
17. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A. Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J; Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913 [TBL] [Abstract][Full Text] [Related]
18. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency. Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212 [TBL] [Abstract][Full Text] [Related]
19. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Singer ST; Addiego JE; Reason DC; Lucas AH Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245 [TBL] [Abstract][Full Text] [Related]
20. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Bray GL; Kroner BL; Arkin S; Aledort LW; Hilgartner MW; Eyster ME; Ragni MV; Goedert JJ Am J Hematol; 1993 Apr; 42(4):375-9. PubMed ID: 8493988 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]